Special Issue "Hormone Therapy"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (30 June 2012)
Dr. John Eden
Department of Reproductive Endocrinology, The University of New South Wiles, Sydney, Australia
Interests: menopause after breast cancer; polycystic ovary syndrome (PCOS); osteoporosis; biofilms; hormone replacement therapy as well as herbal medicine
Some years ago HT was being touted as a treatment for most if not all menopausal women to treat symptoms such as hot flushes as well as a preventive agent for heart disease and osteoporosis. However, since the first publication of the results of the Women's Health Initiative (WHI) in July 2002, HT usage has declined substantially. Much of the female population is now fearful that HT usage may increase their risk of breast cancer. Around a quarter of women will have severe menopausal symptoms as they pass through the menopause transition and some will have symptoms for the rest of their lives. How safe is HRT? How should we manage women who have severe menopausal flushing for years? Which is the best method for managing genitourinary symptoms? These are some of the questions being addressed this this issue.
Dr. John Eden
- hormone therapy
- hormone replacement therapy
- women's health initiative
- nurse's health study
- million women
- studytestosterone (replacement)
- androgen (replacement)